P&U Etoposide 100mg / 5ml Injection
PDF Leaflet Revision Date: 28 July 1999
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of testicular tumors and small-cell lung carcinoma.
Dosage (summary)
50 to 120 mg/mu00b2 daily for 5 days; 100 mg/mu00b2 on alternate days.
Onset of Action / Duration
Onset: Not specified, Duration: Terminal half-life ~8 hours.
Special Populations
- Severe hepatic dysfunction
- Children
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; potential fetal harm.
Key Drug Interactions
- Caution with other myelosuppressive agents
Contraindications
- Hypersensitivity to Etoposide
- Severe hepatic dysfunction
- Severe myelosuppression
- Acute infections
Common side effects
- Nausea
- Vomiting
- Leucopenia
- Thrombocytopenia
- Alopecia
Counselling Points
- Use effective contraception during treatment
- Monitor for signs of myelosuppression
- Avoid extravasation during administration
Serious warnings
- Myelosuppression
- Carcinogenicity
- Anaphylactic reactions
Important Disclaimer
The P&U Etoposide 100mg / 5ml Injection professional information leaflet below is the property of Pfizer and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
